Immunocore (NASDAQ:IMCR) Cut to Strong Sell at Zacks Research

Immunocore (NASDAQ:IMCR) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Monday, Zacks reports.

A number of other equities research analysts also recently weighed in on IMCR. Mizuho raised their price target on Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a report on Tuesday, July 28th. TD Cowen upgraded Immunocore to a “strong-buy” rating in a research report on Monday, August 24th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a report on Thursday, October 15th. Finally, JPMorgan Chase & Co. assumed coverage on Immunocore in a research report on Friday, August 21st. They issued an “overweight” rating and a $50.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $53.00.

Immunocore Stock Performance

Shares of IMCR opened at $32.38 on Monday. Immunocore has a 12-month low of $27.50 and a 12-month high of $40.71. The company has a current ratio of 4.62, a quick ratio of 4.44 and a debt-to-equity ratio of 0.94. The company has a market cap of $1.67 billion, a PE ratio of -49.81 and a beta of 0.82. The stock has a 50-day moving average price of $31.46 and a 200-day moving average price of $31.70.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Friday, November 6th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.11). The company had revenue of $102.22 million during the quarter, compared to the consensus estimate of $152.09 million. Immunocore had a negative return on equity of 7.96% and a negative net margin of 7.48%. As a group, equities analysts forecast that Immunocore will post -0.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Engineers Gate Manager LP lifted its stake in Immunocore by 334.3% in the second quarter. Engineers Gate Manager LP now owns 60,327 shares of the company’s stock worth $1,915,000 after acquiring an additional 46,435 shares during the period. Braidwell LP purchased a new stake in Immunocore in the second quarter worth about $16,552,000. Eversept Partners LP bought a new stake in Immunocore during the 1st quarter valued at approximately $1,183,000. Public Employees Retirement System of Ohio bought a new stake in Immunocore during the 2nd quarter valued at approximately $2,145,000. Finally, Stempoint Capital LP bought a new stake in Immunocore during the 1st quarter valued at approximately $1,916,000. Institutional investors own 84.50% of the company’s stock.

Key Stories Impacting Immunocore

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Shares crossed above their 200-day moving average, a potentially supportive technical signal, despite the earnings miss referenced in the report. Immunocore shares cross above 200-day moving average
• Positive Sentiment: HC Wainwright maintained its Buy rating and an $80 price target—about 147% above the cited $32.38 share price—though the target was reduced from $100. HC Wainwright rating and price target
• Neutral Sentiment: Immunocore presented at the Society for Immunotherapy of Cancer’s 2026 annual meeting; the available article is a slideshow and does not detail specific new clinical findings. SITC 2026 presentation slideshow
• Negative Sentiment: HC Wainwright trimmed its 2027 EPS forecasts for Q1 ($0.17 from $0.18), Q2 ($0.26 from $0.29) and full-year 2027 ($1.34 from $1.36). It raised its Q4 estimate to $0.52 from $0.49, but the overall revisions were lower.
• Negative Sentiment: The cut in HC Wainwright’s price target from $100 to $80 may weigh on sentiment, even with its Buy rating retained.

About Immunocore

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.